These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12594449)

  • 21. Pharmacology of new agents for acute heart failure syndromes.
    Gheorghiade M; Teerlink JR; Mebazaa A
    Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New therapies for heart failure.
    Riggs JM
    RN; 2004 Mar; 67(3):28-32; quiz 33. PubMed ID: 15065491
    [No Abstract]   [Full Text] [Related]  

  • 23. Nesiritide: the latest drug for treating heart failure.
    Fontana D
    Crit Care Nurse; 2006 Feb; 26(1):39-44, 46-7. PubMed ID: 16443809
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic therapies for acutely decompensated heart failure.
    Fonarow GC
    Rev Cardiovasc Med; 2002; 3 Suppl 4():S18-27. PubMed ID: 12439427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.
    Munger MA; Ng TM; Van Tassell BW
    Pharmacotherapy; 2007 May; 27(5):619-25. PubMed ID: 17461695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newer approaches to the pharmacological management of heart failure.
    Rauch H; Motsch J; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):75-81. PubMed ID: 16547437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
    JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levosimendan improves pro/anti-inflammatory cytokines imbalance in male patients with advanced heart failure. A randomized, double-blind, placebo-controlled study.
    Pasqui AL; Maffei S; Di Renzo M; Pompella G; Auteri A; Puccetti L
    Int J Cardiol; 2011 Mar; 147(2):314-5. PubMed ID: 21215479
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of heart failure: a brief review and selected update.
    Unzek S; Francis GS
    Cardiol Clin; 2008 Nov; 26(4):561-71. PubMed ID: 18929231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials.
    Fajardo J; Heywood JT; Patterson JH; Adams K; Chow SL
    Expert Rev Cardiovasc Ther; 2015; 13(7):743-51. PubMed ID: 26028173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New advances and novel treatments in heart failure.
    Smith AL; Brown CS
    Crit Care Nurse; 2003 Feb; Suppl():11-8; quiz 19-20. PubMed ID: 12640965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).
    Gattis WA; O'Connor CM; Hasselblad V; Adams KF; Kobrin I; Gheorghiade M
    Am J Cardiol; 2004 Jun; 93(11):1436-7, A10. PubMed ID: 15165935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nesiritide for the treatment of decompensated heart failure.
    Wylie JV; Tsao L
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):803-13. PubMed ID: 15500426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations on the efficacy and safety of levosimendan in ischemic heart failure.
    Nieminen MS; Sandell EP
    Ital Heart J; 2003 May; 4 Suppl 2():39S-44S. PubMed ID: 14635369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hemodynamic determinants of dyspnea improvement in acute decompensated heart failure.
    Solomonica A; Burger AJ; Aronson D
    Circ Heart Fail; 2013 Jan; 6(1):53-60. PubMed ID: 23152491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF).
    Ezekowitz JA; Hernandez AF; Starling RC; Yancy CW; Massie B; Hill JA; Krum H; Diaz R; Ponikowski P; Metra M; Howlett JG; Gennevois D; O'Connor CM; Califf RM; Fonarow GC
    Am Heart J; 2009 Feb; 157(2):219-28. PubMed ID: 19185628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Shah MR; Frey A; Gheorghiade M;
    Am Heart J; 2003 Feb; 145(2 Suppl):S58-9. PubMed ID: 12594454
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.